Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.

Vinayak S, Tolaney SM, Schwartzberg L, Mita M, McCann G, Tan AR, Wahner-Hendrickson AE, Forero A, Anders C, Wulf GM, Dillon P, Lynce F, Zarwan C, Erban JK, Zhou Y, Buerstatte N, Graham JR, Arora S, Dezube BJ, Telli ML.

JAMA Oncol. 2019 Jun 13. doi: 10.1001/jamaoncol.2019.1029. [Epub ahead of print]

PMID:
31194225
2.

How we treat locally advanced HER2-positive breast cancer.

Exman P, Pernas S, Tolaney SM.

Clin Adv Hematol Oncol. 2019 May;17(5):271-280. No abstract available.

PMID:
31188804
3.

Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study.

Yardley DA, Hart L, Favret A, Blau S, Diab S, Richards D, Sparano J, Beck JT, Richards P, Ward P, Ramaswamy B, Tsai M, Blackwell K, Pluard T, Tolaney SM, Esteva FJ, Truica CI, Alemany C, Volas-Redd G, Shtivelband M, Purkayastha D, Dalal AA, Miller M, Hortobagyi GN.

Clin Breast Cancer. 2019 Feb 28. pii: S1526-8209(18)30793-6. doi: 10.1016/j.clbc.2019.02.007. [Epub ahead of print]

PMID:
31160171
4.

The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders.

Ma C, Hodi FS, Giobbie-Hurder A, Wang X, Zhou J, Zhang A, Zhou Y, Mao F, Angell TE, Andrews CP, Hu J, Barroso-Sousa R, Kaiser UB, Tolaney SM, Min L.

Cancer Immunol Res. 2019 May 14. doi: 10.1158/2326-6066.CIR-18-0613. [Epub ahead of print]

PMID:
31088848
5.

ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases.

Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Dieras V, Müller V, Tagliaferri M, Hannah AL, Cortés J.

Future Oncol. 2019 May 10. doi: 10.2217/fon-2019-0180. [Epub ahead of print]

6.

The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy.

Waks AG, Stover DG, Guerriero JL, Dillon D, Barry WT, Gjini E, Hartl C, Lo W, Savoie J, Brock J, Wesolowski R, Li Z, Damicis A, Philips AV, Wu Y, Yang F, Sullivan A, Danaher P, Brauer HA, Osmani W, Lipschitz M, Hoadley KA, Goldberg M, Perou CM, Rodig S, Winer EP, Krop IE, Mittendorf EA, Tolaney SM.

Clin Cancer Res. 2019 May 6. doi: 10.1158/1078-0432.CCR-19-0173. [Epub ahead of print]

PMID:
31061067
7.

Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial).

Bellon JR, Guo H, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Hudis CA, Krop I, Burstein HJ, Winer EP, Tolaney SM.

Breast Cancer Res Treat. 2019 Jul;176(2):303-310. doi: 10.1007/s10549-019-05238-4. Epub 2019 Apr 19.

PMID:
31004299
8.

Personalized chemotherapy in triple-negative breast cancer: are we ready for prime time?

Barroso-Sousa R, Shapiro GI, Tolaney SM.

Stem Cell Investig. 2019 Feb 22;6:4. doi: 10.21037/sci.2019.02.01. eCollection 2019. No abstract available.

9.

Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, Schneider BP, Shen F, Fuhrman K, Baltay M, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer B, Partridge AH, Hudis CA, Krop IE, Burstein HJ, Winer EP.

J Clin Oncol. 2019 Apr 2:JCO1900066. doi: 10.1200/JCO.19.00066. [Epub ahead of print]

PMID:
30939096
10.

HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance.

Pernas S, Tolaney SM.

Ther Adv Med Oncol. 2019 Mar 19;11:1758835919833519. doi: 10.1177/1758835919833519. eCollection 2019. Review.

11.

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.

Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K.

N Engl J Med. 2019 Feb 21;380(8):741-751. doi: 10.1056/NEJMoa1814213.

PMID:
30786188
12.

The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial.

Barroso-Sousa R, Barry WT, Guo H, Dillon D, Tan YB, Fuhrman K, Osmani W, Getz A, Baltay M, Dang C, Yardley D, Moy B, Marcom PK, Mittendorf EA, Krop IE, Winer EP, Tolaney SM.

Ann Oncol. 2019 Apr 1;30(4):575-581. doi: 10.1093/annonc/mdz047.

PMID:
30753274
13.

Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial.

Adams S, Diamond JR, Hamilton E, Pohlmann PR, Tolaney SM, Chang CW, Zhang W, Iizuka K, Foster PG, Molinero L, Funke R, Powderly J.

JAMA Oncol. 2018 Oct 19. doi: 10.1001/jamaoncol.2018.5152. [Epub ahead of print]

PMID:
30347025
14.

Optimal treatment of early stage HER2-positive breast cancer.

Pernas S, Barroso-Sousa R, Tolaney SM.

Cancer. 2018 Dec 1;124(23):4455-4466. doi: 10.1002/cncr.31657. Epub 2018 Oct 6. Review.

PMID:
30291791
15.

Haemophagocytic lymphohistiocytosis complicating pembrolizumab treatment for metastatic breast cancer in a patient with the PRF1A91V gene polymorphism.

Al-Samkari H, Snyder GD, Nikiforow S, Tolaney SM, Freedman RA, Losman JA.

J Med Genet. 2019 Jan;56(1):39-42. doi: 10.1136/jmedgenet-2018-105485. Epub 2018 Oct 4.

PMID:
30287596
16.

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.

Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, Kuter I, Nanda R, Cassier PA, Delord JP, Gordon MS, ElGabry E, Chang CW, Sarkar I, Grossman W, O'Hear C, Fassò M, Molinero L, Schmid P.

JAMA Oncol. 2019 Jan 1;5(1):74-82. doi: 10.1001/jamaoncol.2018.4224.

PMID:
30242306
17.

Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.

Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L.

Endocr Rev. 2019 Feb 1;40(1):17-65. doi: 10.1210/er.2018-00006. Review.

PMID:
30184160
18.

CDK4/6 inhibition in breast cancer: current practice and future directions.

Pernas S, Tolaney SM, Winer EP, Goel S.

Ther Adv Med Oncol. 2018 Jul 17;10:1758835918786451. doi: 10.1177/1758835918786451. eCollection 2018. Review.

19.

Database Selection and Heterogeneity-More Details, More Credibility-Reply.

Barroso-Sousa R, Barry WT, Tolaney SM.

JAMA Oncol. 2018 Sep 1;4(9):1295-1296. doi: 10.1001/jamaoncol.2018.1231. No abstract available.

PMID:
29955794
20.

Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer.

Stover DG, Gil Del Alcazar CR, Brock J, Guo H, Overmoyer B, Balko J, Xu Q, Bardia A, Tolaney SM, Gelman R, Lloyd M, Wang Y, Xu Y, Michor F, Wang V, Winer EP, Polyak K, Lin NU.

NPJ Breast Cancer. 2018 May 4;4:10. doi: 10.1038/s41523-018-0060-z. eCollection 2018.

21.

De-escalating treatment in the adjuvant setting in HER2-positive breast cancer.

Barroso-Sousa R, Exman P, Tolaney SM.

Future Oncol. 2018 Apr;14(10):937-945. doi: 10.2217/fon-2017-2500. Epub 2018 Mar 28. Review.

PMID:
29589471
22.

Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2.

Incio J, Ligibel JA, McManus DT, Suboj P, Jung K, Kawaguchi K, Pinter M, Babykutty S, Chin SM, Vardam TD, Huang Y, Rahbari NN, Roberge S, Wang D, Gomes-Santos IL, Puchner SB, Schlett CL, Hoffmman U, Ancukiewicz M, Tolaney SM, Krop IE, Duda DG, Boucher Y, Fukumura D, Jain RK.

Sci Transl Med. 2018 Mar 14;10(432). pii: eaag0945. doi: 10.1126/scitranslmed.aag0945.

23.

Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management.

Barroso-Sousa R, Ott PA, Hodi FS, Kaiser UB, Tolaney SM, Min L.

Cancer. 2018 Mar 15;124(6):1111-1121. doi: 10.1002/cncr.31200. Epub 2018 Jan 3. Review.

24.

Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.

Stover DG, Parsons HA, Ha G, Freeman SS, Barry WT, Guo H, Choudhury AD, Gydush G, Reed SC, Rhoades J, Rotem D, Hughes ME, Dillon DA, Partridge AH, Wagle N, Krop IE, Getz G, Golub TR, Love JC, Winer EP, Tolaney SM, Lin NU, Adalsteinsson VA.

J Clin Oncol. 2018 Feb 20;36(6):543-553. doi: 10.1200/JCO.2017.76.0033. Epub 2018 Jan 3.

25.

Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors.

Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, Gydush G, Reed SC, Rotem D, Rhoades J, Loginov D, Livitz D, Rosebrock D, Leshchiner I, Kim J, Stewart C, Rosenberg M, Francis JM, Zhang CZ, Cohen O, Oh C, Ding H, Polak P, Lloyd M, Mahmud S, Helvie K, Merrill MS, Santiago RA, O'Connor EP, Jeong SH, Leeson R, Barry RM, Kramkowski JF, Zhang Z, Polacek L, Lohr JG, Schleicher M, Lipscomb E, Saltzman A, Oliver NM, Marini L, Waks AG, Harshman LC, Tolaney SM, Van Allen EM, Winer EP, Lin NU, Nakabayashi M, Taplin ME, Johannessen CM, Garraway LA, Golub TR, Boehm JS, Wagle N, Getz G, Love JC, Meyerson M.

Nat Commun. 2017 Nov 6;8(1):1324. doi: 10.1038/s41467-017-00965-y.

26.

Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a review.

Freedman RA, Tolaney SM.

Breast Cancer Res Treat. 2018 Feb;167(3):607-614. doi: 10.1007/s10549-017-4560-6. Epub 2017 Nov 4. Review.

PMID:
29103175
27.

Randomized trial of a clinic-based weight loss intervention in cancer survivors.

Brown JC, Yung RL, Gobbie-Hurder A, Shockro L, O'Connor K, Campbell N, Kasper J, Mayer EL, Tolaney SM, Partridge AH, Ligibel JA.

J Cancer Surviv. 2018 Apr;12(2):186-195. doi: 10.1007/s11764-017-0657-5. Epub 2017 Nov 3.

28.

Occurrence and significance of morphologic changes in patients with metastatic triple negative breast cancer treated with Cabozantinib.

Shinagare AB, Somarouthu B, Guo H, Tolaney SM, Ramaiya NH.

Clin Imaging. 2018 Mar - Apr;48:44-47. doi: 10.1016/j.clinimag.2017.09.014. Epub 2017 Sep 28.

PMID:
29028513
29.

Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.

Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM.

JAMA Oncol. 2018 Feb 1;4(2):173-182. doi: 10.1001/jamaoncol.2017.3064.

30.

Optimal Management of Early and Advanced HER2 Breast Cancer.

Hurvitz SA, Gelmon KA, Tolaney SM.

Am Soc Clin Oncol Educ Book. 2017;37:76-92. doi: 10.14694/EDBK_175630. Review.

31.

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer.

Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, Wildiers H, Hudis CA, O'Shaughnessy J, Zamora E, Yardley DA, Frenzel M, Koustenis A, Baselga J.

Clin Cancer Res. 2017 Sep 1;23(17):5218-5224. doi: 10.1158/1078-0432.CCR-17-0754. Epub 2017 May 22. Erratum in: Clin Cancer Res. 2018 Nov 1;24(21):5485.

32.

Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer.

Mamiya H, Tahara RK, Tolaney SM, Choudhry NK, Najafzadeh M.

Ann Oncol. 2017 Aug 1;28(8):1825-1831. doi: 10.1093/annonc/mdx201.

PMID:
28472324
33.

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O'Shaughnessy J, Kalinsky K, Guarino M, Abramson V, Juric D, Tolaney SM, Berlin J, Messersmith WA, Ocean AJ, Wegener WA, Maliakal P, Sharkey RM, Govindan SV, Goldenberg DM, Vahdat LT.

J Clin Oncol. 2017 Jul 1;35(19):2141-2148. doi: 10.1200/JCO.2016.70.8297. Epub 2017 Mar 14.

34.

Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors.

Abramson VG, Supko JG, Ballinger T, Cleary JM, Hilton JF, Tolaney SM, Chau NG, Cho DC, Pearlberg J, Lager J, Shapiro GI, Arteaga CL.

Clin Cancer Res. 2017 Jul 15;23(14):3520-3528. doi: 10.1158/1078-0432.CCR-16-1764. Epub 2016 Dec 28.

35.

Effect of the LIVESTRONG at the YMCA exercise program on physical activity, fitness, quality of life, and fatigue in cancer survivors.

Irwin ML, Cartmel B, Harrigan M, Li F, Sanft T, Shockro L, O'Connor K, Campbell N, Tolaney SM, Mayer EL, Yung R, Freedman RA, Partridge AH, Ligibel JA.

Cancer. 2017 Apr 1;123(7):1249-1258. doi: 10.1002/cncr.30456. Epub 2016 Nov 28.

36.

A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan.

Cleary JM, McRee AJ, Shapiro GI, Tolaney SM, O'Neil BH, Kearns JD, Mathews S, Nering R, MacBeath G, Czibere A, Sharma S, Korn WM.

Invest New Drugs. 2017 Feb;35(1):68-78. doi: 10.1007/s10637-016-0399-7. Epub 2016 Nov 16.

PMID:
27853996
37.

Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.

Tolaney SM, Ziehr DR, Guo H, Ng MR, Barry WT, Higgins MJ, Isakoff SJ, Brock JE, Ivanova EV, Paweletz CP, Demeo MK, Ramaiya NH, Overmoyer BA, Jain RK, Winer EP, Duda DG.

Oncologist. 2017 Jan;22(1):25-32. doi: 10.1634/theoncologist.2016-0229. Epub 2016 Oct 27.

38.

Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study.

Tolaney SM, Nechushtan H, Ron IG, Schöffski P, Awada A, Yasenchak CA, Laird AD, O'Keeffe B, Shapiro GI, Winer EP.

Breast Cancer Res Treat. 2016 Nov;160(2):305-312. Epub 2016 Oct 6.

39.

Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer.

Barroso-Sousa R, Shapiro GI, Tolaney SM.

Breast Care (Basel). 2016 Jun;11(3):167-73. doi: 10.1159/000447284. Epub 2016 Jun 22. Review.

40.

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.

Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, Beeram M, Rasco DW, Hilton JF, Nasir A, Beckmann RP, Schade AE, Fulford AD, Nguyen TS, Martinez R, Kulanthaivel P, Li LQ, Frenzel M, Cronier DM, Chan EM, Flaherty KT, Wen PY, Shapiro GI.

Cancer Discov. 2016 Jul;6(7):740-53. doi: 10.1158/2159-8290.CD-16-0095. Epub 2016 May 23.

41.

Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.

Goel S, Wang Q, Watt AC, Tolaney SM, Dillon DA, Li W, Ramm S, Palmer AC, Yuzugullu H, Varadan V, Tuck D, Harris LN, Wong KK, Liu XS, Sicinski P, Winer EP, Krop IE, Zhao JJ.

Cancer Cell. 2016 Mar 14;29(3):255-269. doi: 10.1016/j.ccell.2016.02.006.

42.

Randomized trial of a physical activity intervention in women with metastatic breast cancer.

Ligibel JA, Giobbie-Hurder A, Shockro L, Campbell N, Partridge AH, Tolaney SM, Lin NU, Winer EP.

Cancer. 2016 Apr 15;122(8):1169-77. doi: 10.1002/cncr.29899. Epub 2016 Feb 12.

43.

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.

LoRusso PM, Li J, Burger A, Heilbrun LK, Sausville EA, Boerner SA, Smith D, Pilat MJ, Zhang J, Tolaney SM, Cleary JM, Chen AP, Rubinstein L, Boerner JL, Bowditch A, Cai D, Bell T, Wolanski A, Marrero AM, Zhang Y, Ji J, Ferry-Galow K, Kinders RJ, Parchment RE, Shapiro GI.

Clin Cancer Res. 2016 Jul 1;22(13):3227-37. doi: 10.1158/1078-0432.CCR-15-0652. Epub 2016 Feb 3.

44.

The evolving understanding of small HER2-positive breast cancers: matching management to outcomes.

Waks AG, Tolaney SM.

Future Oncol. 2015;11(24):3261-71. doi: 10.2217/fon.15.240. Epub 2015 Nov 13. Review.

PMID:
26634944
45.

Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.

Tolaney SM, Boucher Y, Duda DG, Martin JD, Seano G, Ancukiewicz M, Barry WT, Goel S, Lahdenrata J, Isakoff SJ, Yeh ED, Jain SR, Golshan M, Brock J, Snuderl M, Winer EP, Krop IE, Jain RK.

Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):14325-30. doi: 10.1073/pnas.1518808112. Epub 2015 Nov 2.

46.

Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.

Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I, Wolff AC, Carey LA, Moy B, Groarke J, Moslehi J, Krop I, Burstein HJ, Hudis C, Winer EP, Tolaney SM.

JAMA Oncol. 2016 Jan;2(1):29-36. doi: 10.1001/jamaoncol.2015.3709.

47.

Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.

Blackwell K, Burris H, Gomez P, Lynn Henry N, Isakoff S, Campana F, Gao L, Jiang J, Macé S, Tolaney SM.

Breast Cancer Res Treat. 2015 Nov;154(2):287-97. doi: 10.1007/s10549-015-3615-9. Epub 2015 Oct 24.

PMID:
26497877
48.

Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors.

Waks AG, Tolaney SM, Galar A, Arnaout A, Porter JB, Marty FM, Winer EP, Hammond SP, Baden LR.

Breast Cancer Res Treat. 2015 Nov;154(2):359-67. doi: 10.1007/s10549-015-3573-2. Epub 2015 Sep 29.

PMID:
26420402
49.

Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer.

Tolaney SM, Tan S, Guo H, Barry W, Van Allen E, Wagle N, Brock J, Larrabee K, Paweletz C, Ivanova E, Janne P, Overmoyer B, Wright JJ, Shapiro GI, Winer EP, Krop IE.

Invest New Drugs. 2015 Oct;33(5):1108-14. doi: 10.1007/s10637-015-0269-8. Epub 2015 Jul 1.

50.

Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial).

Ruddy KJ, Guo H, Barry W, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Hudis C, Krop IE, Burstein HJ, Winer EP, Partridge AH, Tolaney SM.

Breast Cancer Res Treat. 2015 Jun;151(3):589-96. doi: 10.1007/s10549-015-3426-z. Epub 2015 May 16.

Supplemental Content

Loading ...
Support Center